1832 Asset Management
LEXX icon

1832 Asset Management’s Lexaria Bioscience LEXX Stock Holding History

1832 Asset Management’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,686
Closed -$7.47K – 798
2024
Q2 		$7.47K Hold
2,686
– – ﹤0.01% 791
2024
Q1 		$9.75K Hold
2,686
– – ﹤0.01% 765
2023
Q4 		$3.36K Hold
2,686
– – ﹤0.01% 781
2023
Q3 		$2.69K Hold
2,686
– – ﹤0.01% 801
2023
Q2 		$1.96K Hold
2,686
– – ﹤0.01% 815
2023
Q1 		$7.3K Hold
2,686
– – ﹤0.01% 819
2022
Q4 		$6.61K Buy
+2,686
New +$6.43K ﹤0.01% 836
2022
Q2 		– Sell
-2,686
Closed -$9K – 922
2022
Q1 		$9K Buy
+2,686
New +$10.1K ﹤0.01% 878

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WG
Welch Group Birmingham, Alabama $2.93B AUM 27.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

1832 Asset Management's LEXX Position: Q3 2024 in Review

1832 Asset Management sold out of Lexaria Bioscience (LEXX) in Q3 2024, closing a stake of 2,686 shares — an estimated $7.47K sold.

1832 Asset Management first reported a position in LEXX in Q1 2022 and held it in 8 quarters. The position peaked at $9.75K in Q1 2024. 27 funds tracked by Wall St. Rank hold LEXX as of Q3 2024.

  • 1832 Asset Management reported no remaining Lexaria Bioscience position as of Q3 2024 after selling out during the quarter.
  • 1832 Asset Management sold 2,686 Lexaria Bioscience shares in Q3 2024, an estimated $7.47K.
  • 1832 Asset Management first reported a position in Lexaria Bioscience in Q1 2022 and held it in 8 quarters.
  • 1832 Asset Management's Lexaria Bioscience position peaked at $9.75K in Q1 2024.
  • 27 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q3 2024.

Based on 1832 Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.